STIMULATE study: Statins influence on Minrin upregulation of von Willebrand factor and factor VIII - STIMULATE

Academisch Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•1. Mild hemophilia A: defined as a F VIII deficiency with a F VIII plasma concentration of 10-40 IU mL-1, confirmed on at least two occasions.
•2. or Von Willebrand disease type 1: defined as a VWF deficiency with a VWF plasma concentration of 10-40 IU mL-1, confirmed on at least two occasions.
•3. DDAVP response has been tested at least once before, VWF activity and VWF antigen after DDAVP should not exceed > 200 %.
•4. Age: 18 * 60 years

•1. Moderate/Severe hemophilia A: defined as a F VIII deficiency with a F VIII:C plasma concentration of * 2 IU mL-1, confirmed at at least two occasions.
•2. Von Willebrand disease type 2 or 3
•3. Clinical history of any other hemostatic or thrombotic disorder.
•4. Clinical history of any disorder specified in Appendix C of the study protocol
•5. Use of any medications specified in Appendix C of the study protocol
•6. Medical indication for statin therapy.
•7. Co-enrolment other clinical study
•8. DDAVP response has not previously been tested or vWF antigen and vWF activity increase after previous DDAVP exposure was less than two fold.
•9. First relative (brother/sister) participating in this study

发起方